Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
about
Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsPharmacogenomics in diabetes mellitus: insights into drug action and drug discoveryInfluence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over TimeEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsHyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy.Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.A gene expression resource generated by genome-wide lacZ profiling in the mouse.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.A critical role of solute carrier 22a14 in sperm motility and male fertility in miceCarcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Fainting Fanconi syndrome clarified by proxy: a case reportDe novo expression of sodium-glucose cotransporter SGLT2 in Bowman's capsule coincides with replacement of parietal epithelial cell layer with proximal tubule-like epithelium.SGLT-2 inhibitors in development for type 2 diabetes treatmentSGLT2 mediates glucose reabsorption in the early proximal tubule.Tubular transport: core curriculum 2010.Dapagliflozin for the treatment of type 2 diabetes: a review of the literatureThe proximal tubule in the pathophysiology of the diabetic kidney.Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.Short commentary on empagliflozin and its potential clinical impactLP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetesSGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Clinical, Genetic, and Urinary Factors Associated with Uromodulin ExcretionKnockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitusThe potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusA novel SGLT is expressed in the human kidney.Interpreting adverse signals in diabetes drug development programs.Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.A recurrent deletion in the SLC5A2 gene including the intron 7 branch site responsible for familial renal glucosuria.Thyroid hormone treatment decreases hepatic glucose production and renal reabsorption of glucose in alloxan-induced diabetic Wistar rats.SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.The renal effects of SGLT2 inhibitors and a mini-review of the literature.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
P2860
Q28072765-C14A54ED-0FA0-4F6E-9CF4-3E523EF07D04Q28274686-A8D85DFF-AFA2-42F5-85F1-CB8B5DB1FFB2Q28552106-6583FD9F-4B14-4E3A-BED0-072983058E08Q28732080-F81FFFC0-AB7E-47BC-9C59-441D144220DBQ30410876-E42BD260-1052-4C0F-95BD-B8FD7A6CA6F1Q30426407-D03F02FC-0391-4301-AFAA-FEFE7CFBBABDQ30429061-E91B73B3-DDC2-4CF1-AB5E-A3064E1B9CD7Q30488361-36C2023F-E4CD-4C63-AC92-1DBEE4429007Q30663494-A9FB194B-CDDF-4553-806A-DE72CB449C90Q30827518-2F012EF2-D1A1-427F-8E36-1C0CD574E87AQ33785128-BE98AC9F-3E89-4D9C-B8AC-87A74F0F8F72Q33837017-B22B1262-6DED-4D48-BD8F-42B0EAC6DBA8Q33892759-9E569CCF-C8A5-4415-94BF-1645152FC187Q33983846-62CAE9EF-4616-43AF-8F2F-F10190D92AF7Q34248505-538869A3-92C6-46E2-9797-FD8A8E57FB02Q34457264-266B91D9-D949-4341-B57A-5DC07420BC77Q34477365-560AA7DE-BCF7-4FEE-B970-D27EB51A53F1Q34710819-2DE78CF1-974B-42C4-BC76-0145E6F8217AQ34979592-A7DD2C4F-F2DC-48B5-9F76-1A50CF428AB2Q35049845-4C529A96-03A3-4502-AEBA-BE09EE762852Q35111555-C76F5F29-6421-4DA6-A1AE-A1EEF5E0C3D8Q35528797-5C8977E7-E802-410D-B184-8B465F4E42CEQ35664940-3EA9A532-EB99-450E-BF71-48FEAC5DBBCCQ35906490-02ECB913-94AB-4505-B751-F0D0C44B1E46Q36175431-D794AEF5-756D-4B37-BCCB-6F2F7725A5A3Q36221586-352B6E1B-D777-4965-871A-7234990B77BCQ36372598-F4185E0F-14C7-4193-B87B-638DF21022C4Q36432914-FAC031C6-77FF-4426-886B-8D738E658090Q36527897-8F471D7F-B11C-4387-B9B7-8D5BBBE6E806Q36592820-CFE77E6C-98FD-43D1-A7FC-B123C1DD4C16Q36706015-8C803693-F5AE-4198-A8D6-EB71106DAF43Q36942266-0D7AECF9-E00B-41E0-835C-55ACE6BE5A4FQ37253944-80D159CA-70DD-43DF-965D-C38769311EC0Q37282415-FF986957-667F-446E-85B5-D1E97F31425BQ37286814-A73400B3-C7BB-4B7F-A54B-73C9287879D5Q37575455-27573913-9313-4692-AA0C-5AEADC9789E3Q37575461-8FE5F9B0-B4B9-48D2-B0FB-E815AC457631Q37632127-990989F6-28EF-445A-907F-C71C420C4373Q37661798-15757138-E5C1-454C-9FAD-A6F8A7B72EDBQ37764285-32380A0C-DC90-457E-8629-34D74E4B653D
P2860
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
@en
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
@nl
type
label
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
@en
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
@nl
prefLabel
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
@en
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
@nl
P356
P1476
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target
@en
P2093
René Santer
P304
P356
10.2215/CJN.04010609
P50
P577
2009-11-05T00:00:00Z